Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain

International Journal of Antimicrobial Agents

Volumn 51, Issue 3, 2018, Pages 511-515

  García Castillo, María ^a,b,c   García Fernández, Sergio ^a,b,c   Gómez Gil, Rosa ^d   Pitart, Cristina ^e   Oviaño, Marina ^f,i   Gracia Ahufinger, Irene ^c,g   Díaz Regañón, Jazmín ^h   Tato, Marta ^a,b,c   Cantón, Rafael ^a,b,c   Bou, Germán ⁱ   Rodríguez, Julio García ^d   Gil, Rosa Gómez ^d   Martínez, Luis Martínez ^g   Ahufinger, Irene Gracia ^g   Vila, Jordi ^e   Marco, Francesc ^e   del Castillo, María García ^a   Fernández, Sergio García ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c Red Espanola de Investigacion en Patologia Infecciosa REIPI   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Carbapenemase producing Enterobacteriaceae; Ceftazidime avibactam; OXA 48; Prevalence of carbapenemase

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEMASE; CARBAPENEMASE IMP; CARBAPENEMASE KPC; CARBAPENEMASE NDM; CARBAPENEMASE OXA 48; CARBAPENEMASE VIM; CEFTAZIDIME; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; DISEASE SURVEILLANCE; DRUG ACTIVITY; ENTEROBACTER CLOACAE; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MALE; MIC50; MIC90; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SPAIN; URINARY TRACT INFECTION; URINE SAMPLING; WHOLE GENOME SEQUENCING; ADOLESCENT; CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; URINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SPAIN; URINARY TRACT INFECTIONS; URINE; YOUNG ADULT;

EID: 85041656608     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2018.01.011     Document Type: Article

References (22)

1. Cantón, R., Akóva, M., Carmeli, Y., Giske, C.G., Glupczynski, Y., Gniadkowski, M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18 (2012), 413–431.
2. Otter, J.A., Burgess, P., Davies, F., Mookerjee, S., Singleton, J., Gilchrist, M., et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect 23 (2017), 188–196.
3. Glasner, C., Albiger, B., Buist, G., Tambić Andrašević, A., Canton, R., Carmeli, Y., et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill, 18, 2013, 20525.
4. Albiger, B., Glasner, C., Struelens, M.J., Grundmann, H., Monnet, D.L., European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill, 20, 2015.
5. Oteo, J., Alcaraz, R., Bou, G., Conejo, C., Díaz-Lamas, A.M., Fernández-Martínez, M., et al. Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain. J Antimicrob Chemother 70 (2015), 2916–2918.
6. Ruiz-Garbajosa, P., Hernández-García, M., Beatobe, L., Tato, M., Méndez, M.I., Grandal, M., et al. A single-day point-prevalence study of faecal carriers in long-term care hospitals in Madrid (Spain) depicts a complex clonal and polyclonal dissemination of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71 (2016), 348–352.
7. Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P.R.S., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73 (2013), 159–177.
8. Sharma, R., Park, T.E., Moy, S., Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther 38 (2016), 431–444.
9. van Duin, D., Bonomo, R.A., Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 63 (2016), 234–241.
10. Woodford, N., Cantón, R., Stone, G.G., Irani, P., Bracher, S., Hawkey, P.M., The infection-carbapenem resistance evaluation surveillance trial (iCREST): early results. Abstracts of the twenty-seventh European congress of clinical microbiology and infectious diseases. 2017, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland [Abstract P-0416]. n.d.
11. Clinical and Laboratory Standards Institute, M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. 2015, CLSI, Wayne, PA.
12. The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1; Available from: http://www.eucast.org, 2017 n.d.
13. Monteiro, J., Widen, R.H., Pignatari, A.C., Kubasek, C., Silbert, S., Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 67 (2012), 906–909.
14. Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.
15. Xavier, B.B., Lammens, C., Ruhal, R., Kumar-Singh, S., Butaye, P., Goossens, H., et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surveill, 21, 2016.
16. Oteo, J., Ortega, A., Bartolomé, R., Bou, G., Conejo, C., Fernández-Martínez, M., et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother 59 (2015), 3406–3412.
17. Woodford, N., Xu-McCrae, L., Mushtaq, S., Wu, H.H.T., Ellington, M.J., Lancaster, O., et al. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK). J Antimicrob Chemother, 2017, 10.1093/jac/dkx471.
18. López-Cerero, L., Egea, P., Gracia-Ahufinger, I., González-Padilla, M., Rodríguez-López, F., Rodríguez-Baño, J., et al. Characterisation of the first ongoing outbreak due to KPC-3-producing Klebsiella pneumoniae (ST512) in Spain. Int J Antimicrob Agents 44 (2014), 538–540.
19. Meunier, D., Findlay, J., Doumith, M., Godoy, D., Perry, C., Pike, R., et al. FRI-2 bvgbcfgfb carbapenemase-producing Enterobacter cloacae complex in the UK. J Antimicrob Chemother 72 (2017), 2478–2482.
20. Nordmann, P., Gniadkowski, M., Giske, C.G., Poirel, L., Woodford, N., Miriagou, V., Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 18 (2012), 432–438.
21. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
22. Horcajada, J.P., Shaw, E., Padilla, B., Pintado, V., Calbo, E., Benito, N., et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect 19 (2013), 962–968.